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Abstract: Multi-target-directed ligands (MTDLs) offer new hope for the treatment of multifactorial
complex diseases such as Alzheimer’s Disease (AD). Herein, we present compounds aimed at
targeting the NMDA and the P2X7 receptors, which embody a different approach to AD therapy.
On one hand, we are seeking to delay neurodegeneration targeting the glutamatergic NMDA
receptors; on the other hand, we also aim to reduce neuroinflammation, targeting P2X7 receptors.
Although the NMDA receptor is a widely recognized therapeutic target in treating AD, the P2X7
receptor remains largely unexplored for this purpose; therefore, the dual inhibitor presented
herein—which is open to further optimization—represents the first member of a new class of MTDLs.
Keywords: Alzheimer’s disease; dual target compounds; neuroinflammation; NMDA; P2X7
1. Introduction
Alzheimer’s disease (AD) is an afflicting neurodegenerative disorder that triggers a progressive
loss of neurons and synapses, leading to an irreversible cognitive decline and eventually to
death [1–3]. The two groups of currently approved anti-AD drugs—cholinesterase inhibitors
(donepezil, galantamine, and rivastigmine) [4–6] and N-methyl-D-aspartate receptor (NMDAR)
antagonists (memantine) [7,8]—can, at best, only attenuate AD symptoms for a limited period of
time. Therefore, the development of new effective drugs that may halt the neurodegeneration process
is urgently needed [9–13].
Although the pathophysiology of AD is still not completely understood, it is widely accepted that
the accumulation of extracellular plaques is one of the major hallmarks in AD [14–19]. These plaques
are mainly composed of beta-amyloid peptide and activated microglia; in the first instance, they
produce a neuroprotective inflammatory response to repair damage [20,21].
The ATP-gated P2X7 receptors (P2X7R), widely expressed in the central nervous system
(CNS) [22–24], have been recently identified as an obligate participant in the activation of microglia [25],
where they are especially abundant. Moreover, its physiological activation in other CNS cell lines—as
granular neurons—links to calcium-dependent neuroprotective events such as cAMP response
element-binding (CREB) activation [26]; this is responsible for protection against glutamate-induced
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excitotoxicity and Glycogen synthase kinase 3 (GSK3) phosphorylation, which rescues cells from
apoptosis [27]. On top of that, P2X7R activation can also trigger the non-amyloidogenic cleavage
of the amyloid precursor protein (APP) [28,29]. On the other hand, with higher and chronic levels
of ATP exposure—which is characteristic of AD—the P2X7 receptors up-regulate in microglia [30].
This is responsible for catalyzing inflammatory cascades through the release of IL-1β, ATP, and other
factors that lead to cell apoptosis. In addition to this, it has been demonstrated that P2X7R also releases
glutamate which activates the ionotropic NMDA receptor [31–33].
With physiological levels of glutamate, the NMDA receptor is responsible for learning and
memory processes [34]; however, the beta amyloid oligomers that are formed in AD reduce glutamate
uptake and increase glutamate release, resulting in an elevation of the neurotransmitter levels in
the synaptic cleft [35]. This moderate but chronic stimulation of the NMDA receptor provokes
excitotoxicity, neuronal loss, and the characteristic decline in memory and cognition observed in AD
patients [36]. The clinically approved NMDA receptor antagonist memantine alleviates this process by
blocking the NMDAR in a non-competitive manner [37], allowing the correct function of the receptor
while preventing excitotoxicity [38]. Although its usefulness has been proved extensively, this drug
cannot totally block the neurotoxic cascade of AD.
Taking into account that tackling this complex disease from only one angle seems to be insufficient,
in the last few years several groups have started medicinal chemistry programs aimed at designing
multi-target-directed ligands (MTDLs) for hitting different biological targets for AD [39–41].
Considering the aforementioned role of NMDA and P2X7 receptors in AD, we reasoned that
a drug that could target both receptors simultaneously would be highly beneficial as a potential
treatment of this disease; it could not only halt its progression but also ameliorate its symptoms.
In addition, the similar double-faced neuroprotective–cytotoxic behavior that both receptors display
makes them perfect candidates for this purpose. In light of this, the ideal antagonist would be a
compound that displayed inhibitory potencies in the low micromolar range, allowing the physiological
function of the receptors but, in turn, inhibiting them upon up-regulation or over-activation.
2. Results and Discussion
For this, we envisaged the aminoadamantylcarbohydrazides of general structure I as putative dual
inhibitors (Figure 1). Firstly, I features the amantadine scaffold, which is known to be a micromolar
NMDAR antagonist (IC50 = 92 ± 29 µM) [42]; secondly, the N’-arylcarbohydrazide moiety of 1a is a
compound endowed with nanomolar P2X7R antagonist activity (IC50 = 11.6 ± 2 nM) [43]. Taking into
account the fact that the introduction of a polar alcohol group in 1a led to a reduction of the antagonist
activity of P2X7R (IC50 = 275 ± 50 nM for 1b) [43], we speculated that the compounds of general
structure I might display low micromolar to high nanomolar P2X7R antagonist activities, thus suiting
our aim of designing the first dual NMDAR–P2X7R antagonist with low micromolar activities in
both targets.
In the first instance, seven compounds featuring the general structure I, with diverse substitution
in the aromatic moiety, were prepared and pharmacologically evaluated as P2X7R and NMDAR
antagonists. Compound 2—which features an amide group—was also prepared and pharmacologically
evaluated, with the purpose of assessing the importance of the hydrazide functionality in the linker.
Upon testing this batch of derivatives, in order to optimize the activity values obtained (see below), a
second generation of dual antagonists was prepared starting from memantine—roughly sixty-fold
more potent than amantadine as an NMDAR antagonist (IC50 = 1.5 ± 0.1 µM)—and carbohydrazide
3 [44], a known nanomolar P2X7R antagonist (IC50 = 13 ± 1 nM) (Figure 2). The aim of moving from
general scaffold I to II was to improve the activity of the compounds as NMDAR antagonists, shown
by the previous set of molecules, while preserving the activity against the P2X7 receptor.
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The synthetic route used to prepare general scaffold I, comprehending the derivatives
9a–g and its analogue 2, is depicted in Scheme 1. Starting from the commercially available
1-adamantanecarboxylic acid 4, and following the procedure reported by Schreiner and co-workers,
the N-Boc protected amino acid 6 was prepared in a good overall yield [45]. In order to explore
the structure–activity relati nship (SAR) of the aromatic moiet , 6 was c upled, using EDC
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimid ) a d HOBt (1-Hydroxybenzotriazole), with a range
of seven aromatic hydrazines, 7a–g, bearing diff rent substituents in the p enyl group. Finally,
the des red compounds 9a–g were obtained upon Boc cle vage with hydrochloric acid in 1,4-dioxane.
The amide 2, bearing a modified link r, was accessed following the aforementioned route but
reacting 6 with 2-chlorobenzylamine. The pure products 9a–g and 2, were fully characterized and
pharmacologically evaluated (see below).
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Scheme 1. Synthetic route for the first generati nds, featuring general scaffold I.
Reag nts and conditions: (a) HNO3, H2SO4, acetonitrile, 0 ◦C, 88% yield; (b) HCl, H2O, reflux,
6 days, 46% yield [45]; (c) (Boc)2O, NaOH, THF, 45% yield; (d) 7a–g, HOBt, EDC, H2Cl2; (e) HCl,
1,4-dioxane; (f) NaOH, 14–38% overall yield from 6.
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Scheme 2. Synthetic route for the second generation of compounds, featuring general scaffold II.
Reagents and conditions: (a) HNO3, fuming H2SO4, acetonitrile, 0 ◦C, quantitative yield; (b) HCl, H2O,
reflux, 6 days, 50% yield [45]; (c) (Boc)2O, NaOH, THF, 52% yield; (d) 13a-b, HOBt, EDC, CH2Cl2;
(e) HCl, 1,4-dioxane; (f) NaOH, 25–28% overall yield from 12.
Amino acid 11 was prepared using a similar synthetic route, starting from 5,7-dimethyladamantan
ecarboxylic acid, 10, but under hardened reaction conditions [45]. After N-protection, coupling with
2-chlorophenylhydrazine or 3,5-dichloro-4-hydrazinopyridine, and deprotection, carbohydrazides 15a–b
were obtained (Scheme 2).
All new compounds were evaluated for their antagonistic effects on 2′(3′)-O-(4-benzoylbenzoyl)-ATP
(BzATP)-induced ethidium bromide uptake in human embryonic kidney 293 (HEK 293) cells, stably
expressing the human P2X7 receptor, using P2X7 receptor antagonist AZD9056—AstraZeneca’s clinical
drug candidate [46]—as a positive control. Inspection of the results shown in Table 1 revealed that,
with the sole exception of amide 2, all the new compounds showed activities in the micromolar range
and only the IC50 value of 9g was determined. The comparison of the IC50 values of 1a, 1b, and 9g
(11.6 nM, 275 nM, and 6.0 µM, respectively) highlights that the introduction of a polar group in the
adamanta e scaffold is deleterious for the P2X7 antagoni t activity and that the presence of t e basic
amino group is even worse than that of the non-basic alcohol group. However, taki g into account
that we anted to design a compound endowed with low micromolar inhibitory potencies against
both the P2X7 and NMDA rece tors, compound 9g suited our purpose.
Additionally, to evaluate whether the synthesized compounds were able to antagonize the NMDA
receptors, we measured their effects on the increase in intracellular calcium evoked by NMDA (100 µM,
in the presence of 10 µM of glycine) on rat-cultured cerebellar granule neurons [47]. All the compounds
were only able to inhibit NMDA in the high micromolar range (see Table S1 in the Supplementary
Material), indicating that the addition of the phenyl hydrazide moiety is highly detrimental for NMDA
activity. The best compound of the series, 9g, with an IC50 = 468 ± 23 µM, was roughly five-fold less
potent than amantadine.
Taking into account the fact that the 3,5-dimethyl derivative of amantadine (i.e., memantine)
is 60-fold more potent as an NMDA inhibitor than amantadine [48], we envisaged a second series
of derivatives featuring the memantine moiety. Hydrazide 3, featuring two methyl groups in the
adamantane scaffold, was reported to be a nanomolar P2X7 inhibitor [44], reinforcing the suitability
of this strategy to obtain balanced inhibitory potencies in both receptors. He ce, while the addition
of the two methyl groups to the polycyclic scaffold of he adamantane should not be de rimental for
P2X7R antagonistic effects, we h ped that their insertion ould optimize the activity in the NMDA
receptor, leading to a dual micromolar inhibitor of both receptors.
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Considering that the most promising compound, 9g, in both previous pharmacological
evaluations, P2X7R and NMDAR, featured an o-chloro substitution in the phenyl ring, this motif
was the one selected for the right-hand side of the structure of our compounds. In addition to this, we
decided to prepare 15a due to its similarity with 3 (see Figure 2).
Pleasingly, upon testing with the P2X7R, the IC50 of 15a and 15b were only slightly higher than
that of 9g, reinforcing our hypothesis that the introduction of the two-methyl groups would not be
deleterious for the P2X7R antagonist activity (Table 1). However, contrary to our expectations, 15a and
15b were unable to significantly inhibit the NMDA receptor even at millimolar concentrations (see
Figure 3 and Supplementary Material for details).
Table 1. Antagonistic activity in hP2X7-expressing HEK293 cells a.
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3. Conclusions
To sum arize, we have synthesize , c aracterized and evaluated a series of novel
adamantylcarbohydrazides as potential dual NMDAR and P2X7R antagonists. While three derivatives
displayed low micromolar activities as P2X7R antagonists, only 9g showed some activity as an NMDA
receptor antagonist. Compound 9g is, to the best of our knowledge, the first dual antagonist of
both receptors.
4. Materials and Methods
4.1. Chemical Synthesis
4.1.1. General Methods
Melting points were determined in open capillary tubes with an MFB 595010 M Gallenkamp.
A Varian Mercury 400 spectrometer recorded 400 MHz 1H-NMR spectra and 100.6 MHz 13C-NMR
spectra. The chemical shifts are reported in ppm (δ scale) relative to internal tetramethylsilane,
and coupling constants are reported in hertz (Hz). Assignments given for the NMR spectra of
the new compounds have been carried out on the basis of COSY 1H/13C (gHSQC and gHMBC
sequences), COSY 1H/1H (standard procedures). IR spectra were run on PerkinElmer Spectrum RX I
spectrophotometer (Waltham, MA, USA). Absorption values are expressed as wavenumbers (cm−1);
only significant absorption bands are given. The GC/MS analysis was carried out in an inert Agilent
Technologies 5975 gas chromatograph (Agilent Technologies Inc., Santa Clara, CA, USA) equipped
with a Agilent 122-5532 DB-5MS 1b (30 m × 0.25 mm) capillary column with a stationary phase of
phe ylmethylsilicon (5% diphenyl–95% dimethylpolysiloxane), using the following conditions: initial
temp rat e of 50 ◦C (1 min), with gradient of 10◦C/min u to 300 ◦C, and a temper ure in the
sourc of 250 ◦C, solv nt delay (SD) of 4 min, and a pressure f 7.35 psi. Accurate mass measurements
were obtained using the ESI technique. Absorption thin-layer chromatography was performed with
aluminum-backed sheets with silica gel 60 F254 (Merck, Darmstadt, Germany, ref 1.05554), and spots
were visualized with UV light and 1% aqueous solution of KMnO4.
4.1.2. Synthesis of the Starting Acids 6 and 12 [45]
3-Acetamidoadamantane-1-carboxylic acid. The compound 1-Adamantane carboxylic acid, 4, (5.0 g,
27.7 mmol) was suspended in 70% HNO3 (4.0 mL) and cooled at 0 ◦C with an ice bath. Using an
addition funnel, 98% H2SO4 (30 mL) was added dropwise, at such a rate that the temperature was kept
at 0 ◦C or below. The reaction mixture was stirred for 2 h at 0 ◦C, whereupon acetonitrile (20 mL) was
added via an addition funnel, at such a rate that the reaction mixture was kept at 0 ◦C. After all the
acetonitrile was added, the reaction was stirred at 0 ◦C for 3 h. The reaction mixture was then poured
over ice (ca. 200 g), with shaking, and was allowed to warm to room temperature. The colorless solid
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was then filtered over vacuum, washed with water, and dried overnight to give the title compound
(5.8 g, 88.1% yield). The 1H-NMR matched the data previously reported in the bibliography [46].
3-Aminoadamantane-1-carboxylic acid hydrochloride, 5·HCl. The compound 3-acetamidoadamantane-
1-carboxylic acid (5.8 g, 24.4 mmol), water (13.5 mL), and 37% hydrochloric acid (33.0 mL) were added
to a 3-neck round bottom flask equipped with a reflux condenser, thermometer, and a mechanical
stirrer; the mixture was heated at reflux for 6 days. After cooling at 0 ◦C with an ice bath, the white
precipitate solid was carefully filtered. The solid obtained was then dried under vacuum for 1 day
to afford 5·HCl (2.6 g, 45.9% yield). The 1H-NMR matched the data previously reported in the
bibliography [46].
3-[(tert-Butoxycarbonyl)amino]adamantane-1-carboxylic acid, 6. Aqueous 2 M NaOH (10 mL) and
di-tert-butyl dicarbonate (2.52 g, 11.7 mmol) were added to a mixture of 5·HCl (2.6 g, 11.2 mmol)
in THF (26 mL). After stirring for 16 h at room temperature, the reaction was cooled in an ice bath.
Upon neutralization with aqueous 2 M HCl, the mixture was partitioned into ethyl acetate and water.
The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated under
reduced pressure to give impure 6 (2.66 g). After purification by crystallization from acetonitrile,
6 (1.5 g, 45.3% yield) was obtained as a white solid. The 1H-NMR matched the data previously
reported in the bibliography [46].
3-Acetamido-5,7-dimethyladamantane-1-carboxylic acid. The compound 3,5-dimethyladamantane
-1-carboxylic acid (2.0 g, 9.6 mmol) was suspended in 70% HNO3 (6.0 mL) and cooled to 0 ◦C with an
ice bath. Using an addition funnel, 98% H2SO4 (10 mL) was added dropwise at such a rate that the
temperature was kept at 0 ◦C or below. The mixture was stirred for 10 min and 20–30% oleum (3.5 mL)
was added dropwise. The whole mixture was stirred for 30 min at 0 ◦C and 1 h at room temperature.
Upon cooling again at 0 ◦C, acetonitrile (6.0 mL) was added and the mixture stirred for 10 min at 0 ◦C
and 3 h at room temperature. Finally, the mixture was poured onto ice (ca. 200 g) and kept at 5 ◦C
overnight. The white precipitate was collected via suction filtration and dried for 1 h to obtain the title
compound as a white solid in quantitative yield [46].
3-Amino-5,7-dimethyladamantane-1-carboxylic acid hydrochloride, 11·HCl. The compound 3-acetamido
-5,7-dimethyladamantane-1-carboxylic acid (2.5 g, 9.42 mmol) was heated in 37% HCl (60 mL) for
5 days at reflux in a round flask equipped with a reflux condenser, thermometer, and a mechanical
stirrer. After removal of the acid under reduced pressure, the crude product was washed with
ethyl acetate and collected via suction filtration. The compound was dried in a desiccator over P2O5
overnight to give 11·HCl (1.23 g, 50% yield) as a white solid. The 1H NMR matched the data previously
reported in the bibliography [45].
3-tert-Butoxycarbonylamino-5,7-dimethyladamantane-1-carboxylic acid, 12. The compound Di-tert-butyl
dicarbonate (1.03 g, 4.73 mmol) was added to a round flask containing 11·HCl (1.23 g, 4.73 mmol)
in THF (15 mL) and aqueous 2 M NaOH (6 mL). After stirring for 16 h at room temperature, the
reaction was cooled into an ice bath. Following this, it was neutralized with aqueous 2 M HCl and
partitioned into ethyl acetate and water. The organic layer was separated, dried over Na2SO4, filtered
and concentrated under reduced pressure to give a white solid (1.15 g). The crude product was purified
by crystallization from acetonitrile to give 12 (800 mg, 52% yield). The 1H-NMR matched the data
previously reported in the bibliography [45].
4.1.3. General Procedures for the Synthesis of Carbohydrazides 9a–f or 15a–b.
General Procedure A. HOBt (162 mg, 1.2 mmol) and EDC (230 mg, 1.2 mmol) were added to a
suspension of 6 (295 mg, 1 mmol) or 12 (323 mg, 1 mmol) in CH2Cl2 and the whole mixture was stirred
at room temperature for 2 h. The resulting mixture was then added dropwise via an addition funnel
to a solution of the desired hydrazine (2 mmol, see each example for specific weights) in CH2Cl2,
maintaining the temperature range between 0–10 ◦C. The mixture was washed with water and aqueous
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K2CO3, and the organic layer was dried over anhydrous Na2SO4, filtered and concentrated under
reduced pressure, to yield the corresponding carbamate 8a–f or 14a–b.
General Procedure B. A solution of the corresponding crude carbamate precursor 8a–f or 14a–b
(ca. 1 mmol) in CH2Cl2 (20 mL) had 4 M HCl in 1,4-dioxane (10 mL) added to it; the solution was left
stirring at room temperature for 16 h. Once the reaction was completed, the mixture was extracted with
aqueous 1 M HCl and the aqueous phase was then brought to basic pH with excess of aqueous 2 M
NaOH. Upon extraction with CH2Cl2, the joined organic extracts were dried over anhydrous Na2SO4,
filtered and concentrated under reduced pressure. The crude reaction product was crystallized from
ethyl acetate, to yield the desired pure product 9a–f or 15a–b.
4.1.4. Characterization Data for 2, 9a–f, and 15a–b.
3-Amino-N-(2-chlorobenzyl)adamantane-1-carboxamide, 2. Following general procedure A but using
2-chlorobenzylamine (283 mg, 2 mmol) instead of a hydrazine, the expected carbamate that was
obtained was subsequently treated with the general procedure B to yield 2 as a white solid (111 mg,
35% overall yield). mp = 186–189 ◦C. IR (ATR): 667, 744, 868, 1036, 1049, 1261, 1287, 1359, 1408,
1439, 1467, 1529, 1628, 2139, 2842, 2899, 3333 cm−1. 1H-NMR (400 MHz, CDCl3) δ: 1.48 (s, 2H, NH2),
1.56–1.63 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.67 (s, 2H, 2-H2), 1.72–1.80 [m, 4H, 8(9)-H2], 2.20
[m, 2H, 5(7)-H], 4.50 (d, J = 6.0 Hz, 2H, NHCH2), 6.05 (s, 1H, CONH), 7.19–7.25 (complex signal, 2H)
and 7.31–7.37 (complex signal, 2H) (Ar-H). 13C-NMR (100.6 MHz, CDCl3) δ: 29.5 [CH, C5(7)], 35.2
(CH2, C6), 38.2 [CH2, C8(9)], 41.5 (CH2, NHCH2), 43.1 (C, C1), 45.0 [CH2, C4(10)], 47.81 (CH2, C2),
47.84 (C, C3), 127.1 (CH), 128.9 (CH), 129.5 (CH), 130.2 (CH), 133.6 (C, C2’), 135.8 (C, C1’), 176.8 (C,
CO). HRMS-ESI+ m/z [M + H]+ calculated for [C18H23ClN2O+ H]+: 319.1572, found: 319.1574.
3-Amino-N'-[2-(trifluoromethyl)phenyl]adamantane-1-carbohydrazide, 9a. Compound 8a was obtained
following general procedure A and, without further purification, 8a was reacted with
2-(trifluoromethyl)phenylhydrazine (7a), 352 mg, 2 mmol) following general procedure B to give 9a
as a white solid (67 mg, 19% yield). mp = 213–216 ◦C. IR (ATR): 641, 695, 749, 899, 920, 1033, 1059, 1103,
1116, 1134, 1155, 1245, 1271, 1323, 1454, 1483, 1501, 1547, 1584, 1615, 1653, 2847, 2914, 3354 cm−1. 1H-NMR
(400 MHz, CDCl3) δ: 1.45 (s, 2H, NH), 1.56–1.68 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.78 (s, 2H,
2-H2), 1.82–1.92 [m, 4H, 8(9)-H2], 2.26 [m, 2H, 5(7)-H], 6.56 (s, 1H, NH), 6.93 (d, J = 7.6 Hz, 1H, 6’-H), 6.96
(d, J = 7.6 Hz, 1H, 4’-H), 7.39 (t, J = 7.6 Hz, 1H, 5’-H), 7.51 (d, J = 8.4 Hz, 1H, 3’-H). 13C-NMR (100.6 MHz,
CDCl3) δ: 29.4 [CH, C5(7)], 35.0 (CH2, C6), 37.9 [CH2, C8(9)], 42.6 (C, C1), 44.9 [CH2, C4(10)], 47.4 (CH2,
C2), 47.7 (C, C3), 113.2 (CH, C6’), 115.3 (q, J = 29.5 Hz , C, C2’), 120.3 (C, C4’), 124.5 (q, J = 269.3 Hz,
C, CF3), 126.6 (q, J = 5.4 Hz, CH, C3’), 132.9 (CH, C5’), 145.9 (C, C1’), 176.6 (C, CO). HRMS-ESI+ m/z
[M + H]+ calculated for [C18H22F3N3O+ H]+: 354.1788, found: 354.1794.
3-Amino-N'-(2,6-dichlorophenyl)adamantane-1-carbohydrazide, 9b. Compound 8b was obtained
following general procedure A and, without further purification, 8b was reacted with
2,6-dichlorophenylhydrazine (7b, 354 mg, 2 mmol) following general procedure B to give 9b as
a colourless solid (135 mg, 38% yield). mp = 153–156 ◦C. IR (ATR): 713, 760, 863, 935, 1085, 1304, 1418,
1444, 1524, 1576, 1594, 1653, 2020, 2847, 2914, 2930, 3136, 3322 cm−1. 1H-NMR (400 MHz, CDCl3) δ: 1.25
(broad signal, 2H, NH2), 1.50–1.62 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.68 (s, 2H, 2-H2), 1.71–1.82
[complex signal, 4H, 8(9)-H2], 2.19 [m, 2H, 5(7)-H], 6.78 (d, J = 4.8 Hz, 1H, NH), 6.88 (t, J = 8.9 Hz, 1H,
4’-H), 7.23 [d, J = 8.0 Hz, 2H, 3’(5’)-H], 7.92 (d, J = 5.2 Hz, 1H, NH). 13C-NMR (100.6 MHz, CDCl3) δ:
29.4 [CH, C5(7)], 35.1 (CH2, C6), 37.8 [CH2, C8(9)], 42.7 (C, C1), 45.0 [CH2, C4(10)], 47.5 (CH2, C2), 47.6
(C, C3), 123.9 (CH, C4’), 125.8 [C, C2’(6’)], 128.9 [CH, C3’(5’)], 141.3 (C, C1’), 175.4 (C, CO). HRMS-ESI+
m/z [M + H]+ calculated for [C17H21Cl2N3O+ H]+: 354.1134, found: 354.1140.
3-Amino-N'-(2,3-dichlorophenyl)adamantane-1-carbohydrazide, 9c. Compound 8c was obtained
following general procedure A and, without further purification, 8c was reacted with
2,3-dichlorophenylhydrazine (7c, 354 mg, 2 mmol) following general procedure B to give 9c as a
light yellow solid (127 mg, 36% yield). mp = 215–219 oC. IR (ATR): 767, 912, 938, 1041, 1106, 1137,
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1170, 1266, 1287, 1421, 1449, 1491, 1578, 1648, 2842, 2894, 3348 cm−1. 1H-NMR (400 MHz, DMSO) δ:
1.42–1.57 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.63 (s, 2H, 2-H2), 1.70–1.80 [complex signal, 4H,
8(9)-H2], 2.10 [s, 2H, 5(7)-H], 6.61 (dd, J = 8.0 Hz, J’ = 1.6 Hz, 1H, 6’-H), 6.95 (dd, J = 8.0 Hz, J’ = 1.6 Hz,
1H, 4’-H), 7.15 (t, J = 8.0 Hz, 1H, 5’-H), 7.58 (s, 1H, NH). 13C-NMR (100.6 MHz, DMSO) δ: 29.3 [CH,
C5(7)], 35.2 (CH2, C6), 37.7 [CH2, C8(9)], 41.9 (C, C1), 44.9 [CH2, C4(10)], 47.3 (CH2, C2), 47.6 (C, C3),
111.0 (CH, C6’), 115.1 (C, C3’), 119.5 (CH, C4’), 128.4 (CH, C5’), 131.8 (C, C2’), 147.2 (C, C1’), 176.1 (C,
CO). HRMS-ESI+ m/z [M + H]+ calculated for [C17H21Cl2N3O+ H]+: 354.1134, found: 354.1140.
3-Amino-N'-[2-chloro-4-(trifluoromethyl)phenyl]adamantane-1-carbohydrazide, 9d. Compound 8d was
obtained following general procedure A and, without further purification, 8d was reacted with
2-chloro-4-(trifluromethyl)phenylhydrazine (7d, 421 mg, 2 mmol) following general procedure B to
give 9d as a light orange solid (54 mg, 14% yield). mp = 185–186 ◦C. IR (ATR): 659, 822, 881, 899, 930,
1046, 1111, 1256, 1416, 1491, 1578, 1612, 1653, 2899, 2925, 3198, 3385, 3627 cm−1. 1H-NMR (400 MHz,
DMSO) δ: 1.40–1.60 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.64 (s, 2H, 2-H2), 1.70–1.88 [complex
signal, 4H, 8(9)-H2], 2.11 [s, 2H, 5(7)-H], 6.81 (d, J = 8.0 Hz, 1H, 6’-H), 7.45–7.60 (complex signal, 2H,
3’-H and 5’-H), 7.56 (broad s, 1H, NH). 13C-NMR (100.6 MHz, DMSO) δ: 29.2 [CH, C5(7)], 35.2 (CH2,
C6), 37.7 [CH2, C8(9)], 41.9 (C, C1), 44.9 [CH2, C4(10)], 47.2 (CH2, C2), 47.6 (C, C3), 112.8 (q, J = 31.0 Hz,
C, C4’), 114.9 (CH, C6’), 121.4 (C, C2’), 123.8 (q, J = 273.0 Hz, CF3), 125.8 (broad signal, CH, C3’), 133.3
(CH, C5’), 145.8 (C, C1’), 176.1 (C, CO). HRMS-ESI+ m/z [M + H]+ calculated for [C18H21Cl F3N3O+
H]+: 388.1398, found: 388.1404.
3-Amino-N'-(3,5-dichloropyridin-4-yl)adamantane-1-carbohydrazide, 9e. Compound 8e was obtained
following general procedure A and, without further purification, 8e was reacted with
3,5-dichloro-4-hydrazinopyridine (7e, 356 mg, 2 mmol) following general procedure B to give 9e
as a white solid (106 mg, 30% yield). mp = 191–192 oC. IR (ATR): 729, 793, 886, 935, 1000, 1083, 1090,
1225, 1279, 1395, 1444, 1475, 1540, 1558, 1589, 1659, 1958, 1997, 2077, 2153, 2206, 2341, 2909, 3173 cm−1.
1H-NMR (400 MHz, CDCl3) δ: 1.25–1.42 (broad s, 2H, NH), 1.54–1.63 [complex signal, 6H, 6-H2 and
4(10)-H2], 1.71 (s, 2H, 2-H2), 1.74–1.85 [complex signal, 4H, 8(9)-H2], 2.23 [m, 2H, 5(7)-H], 6.81 (s, 1H,
NH), 7.87 (s, 1H, NH), 8.29 [s, 2H, 2’(6’)-H]. 13C-NMR (100.6 MHz, CDCl3) δ: 29.4 [CH, C5(7)], 35.0
(CH2, C6), 37.8 [CH2, C8(9)], 42.8 (C, C1), 44.9 [CH2, C4(10)], 47.4 (CH2, C2), 47.6 (C, C3), 120.6 [C,
C3’(5’)], 147.3 (C, C4’), 148.4 [CH, C2’(6’)], 175.5 (C, CO) HRMS-ESI+ m/z [M + H]+ calculated for
[C16H20Cl2N4O+ H]+: 355.1087, found: 355.1094.
3-Amino-N'-(3-chloro-2-fluorophenyl)adamantane-1-carbohydrazide, 9f. Compound 8f was obtained
following general procedure A and, without further purification, 8f was reacted with
3-chloro-2-flurophenylhydrazine (7f, 321 mg, 2 mmol) following general procedure B to give 9f
as a yellowish solid (84 mg, 25% yield). mp = 200–202 ◦C. IR (ATR): 708, 762, 814, 920, 935, 943,
1044, 1093, 1124, 1219, 1284, 1457, 1470, 1506, 1584, 1607, 1648, 1984, 2847, 2899, 3307 cm−1. 1H-NMR
(400 MHz, DMSO) δ: 1.00–1.42 [complex signal, 6H, 6-H2 and 4(10)-H2], 1.62 (s, 2H, 2-H2), 1.68–1.78
[complex signal, 4H, 8(9)-H2], 2.10 [broad s, 2H, 5(7)-H], 6.61 (t, J = 8.0 Hz, 1H, 6’-H), 6.82 (t, J = 7.6 Hz,
1H, 4’-H), 6.99 (t, J = 7.6 Hz, 1H, 5’-H), 7.83 (s, 1H, NH). 13C-NMR (100.6 MHz, DMSO) δ: 29.3 [CH,
C5(7)], 35.2 (CH2, C6), 37.7 [CH2, C8(9)], 41.9 (C, C1), 44.8 [CH2, C4(10)], 47.2 (CH2, C2), 47.7 (C, C3),
112.1 (CH, C6’), 118.7 (CH, C4’), 119.5 (d, J = 14.6 Hz, CH, C3’), 125.2 (d, J = 4.2 Hz, CH. C5’), 139.9 (d,
J = 10.2 Hz, C, C1’), 145.6 (d, J = 241.5 Hz, C, C2’), 176.2 (C, CO). HRMS-ESI+ m/z [M + H]+ calculated
for [C17H21ClFN3O+ H]+: 338.1430, found: 338.1439.
3-Amino-N'-(2-chlorophenyl)adamantane-1-carbohydrazide, 9g. Compound 8g was obtained following
general procedure A and, without further purification, 8g was reacted with 2-chlorophenylhydrazine
(7g, 285 mg, 2 mmol) following general procedure B to give 9g as a pale orange solid (90 mg, 28%
yield). mp = 220–222 oC. IR (ATR): 734, 902, 925, 1033, 1046, 1292, 1442, 1496, 1545, 1586, 1594, 1646,
2904, 2925, 3322 cm−1. 1H-NMR (400 MHz, CDCl3) δ: 1.42 (broad s, 2H, NH), 1.56-1.67 [complex signal,
6H, 6-H2 and 4(10)-H2], 1.75 (s, 2H, 2-H2), 1.76–1.87 [complex signal, 4H, 8(9)-H2], 2.23 [s, 2H, 5(7)-H],
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6.43 (broad s, 1H, NH), 6.80 (dd, J = 8.0 Hz, J’ = 1.6 Hz, 1H, 6’-H), 6.83 (td, J = 8.0 Hz, J’ = 1.6 Hz, 1H,
4’-H), 7.13 (td, J = 8.0 Hz, J’ = 1.6 Hz, 1H, 5’H), 7.27 (dd, J = 8.0 Hz, J’ = 1.6 Hz, 3’H), 7.54 (broad s,
1H, NH). 13C-NMR (100.6 MHz, CDCl3) δ: 29.4 [CH, C5(7)], 35.1 (CH2, C6), 37.9 [CH2, C8(9)], 42.6 (C,
C1), 44.9 [CH2, C4(10)], 47.5 (CH2, C2), 47.7 (C, C3), 113.4 (CH, C6’), 119.9 (C, C2’), 121.5 (CH, C4’),
127.6 (CH, C5’), 129.5 (CH, C3’), 144.1 (C, C1’), 176.5 (C, CO). HRMS-ESI+ m/z [M + H]+ calculated for
[C17H22ClN3O+ H]+: 320.1524, found: 320.1528.
3-Amino-N'-(3,5-dichloropyridin-4-yl)-5,7-dimethyladamantane-1-carbohydrazide, 15a. Crude 14a was
obtained from 12 (323 mg, 1 mmol) following general procedure A. Without further purification,
14a was reacted with 3,5-dichloro-4-hydrazinopyridine 13a (356 mg, 2 mmol) following general
procedure B to give 15a as a white solid (96 mg, 25% yield). mp = 300–302 ◦C. 1H NMR (400 MHz,
CDCl3) δ: 0.91 (s, 6H, CH3), 1.12 (broad s, 2H, 6-H2), 1.20-1.27 [complex signal, 4H, 4(10)-H2], 1.42–1.48
[complex signal, 4H, 8(9)-H2], 1.58 (s, 2H, 2-H2), 6.80 (s, 1H, NH), 7.93 (s, 1H, NH), 8.29 [s, 2H, 2’(6’)-H].
13C-NMR (100.6 MHz, CDCl3) δ: 29.6 (CH3, CH3), 32.9 [C, C5(7)], 44.1 [CH2, C8(9)], 44.2 (C, C1), 46.1
(CH2, C2), 49.3 (C, C3), 49.5 (CH2, C6), 51.4 [CH2, C4(10)], 120.6 [CH, C3’(5’)], 147.2 (C, C4’), 148.3 [CH,
C2’(6’)], 175.4 (C, CO). HRMS-ESI+ m/z [M + H]+ calculated for [C18H24Cl2N4O+ H]+: 383.1400, found:
383.1404.
3-Amino-N'-(2-chlorophenyl)-5,7-dimethyladamantane-1-carbohydrazide, 15b. Crude 14b was obtained
from 12 (323 mg, 1 mmol) following general procedure A. Without further purification, 14b was reacted
with 2-chlorophenylhydrazine 13b (285 mg, 2 mmol) following general procedure B to give 15b as a
white solid (97 mg, 28% yield). mp = 280–282 ◦C. IR (ATR): 646, 736, 1031, 1230, 1289, 1356, 1390, 1449,
1540, 1648, 2480, 2857, 2930, 3245, 3297 cm-1. 1H NMR (400 MHz, CD3OD) δ: 0.96 (s, 6H, CH3), 1.19
(broad s, 2H, 6-H2), 1.29–1.37 [complex signal, 4H, 4(10)-H2], 1.55 [broad s, 4H, 8(9)-H2], 1.69 (s, 2H,
2-H2), 6.76–6.82 (complex signal, 2H, 4’-H and 6’-H), 7.15 (dt, J = 8.0 Hz, J’ = 1.6 Hz, 1H, 5’-H), 7.25 (dd,
J = 8.0 Hz, J’ = 1.6 Hz, 1H, 3’-H). 13C-NMR (100.6 MHz, CD3OD) δ: 30.1 (CH3, CH3), 33.9 [C, C5(7)],
45.0 (C, C1), 45.1 [CH2, C8(9)], 45.4 (CH2, C2), 50.5 (CH2, C6), 50.6 [CH2, C4(10)], 51.1 (CH2, C3), 114.2
(CH, C6’), 120.1 (C, C2’), 121.5 (CH, C4’), 128.7 (CH, C5’), 130.3 (CH, C3’), 145.9 (C, C1’), 178.8 (C, CO).
HRMS-ESI+ m/z [M + H]+ calculated for [C19H26ClN3O+ H]+: 348.1764, found: 348.1801.
4.2. P2X7 Receptor Antagonist Activity. Dye Uptake Using the Ethidium Ion Assay
HEK293 cells stably expressing the P2X7 receptor were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and
antibiotics (50 U/mL penicillin and 50 mg/mL streptomycin) in a humidified 5% CO2 atmosphere
at 37 ◦C. We used Lipofectamine as a transfection reagent with a pcDNA3.1 vector-based plasmid
harbouring hP2X7R (Invitrogen, Waltham, MA, USA). After diluting to 2.5 × 106 cells/mL, a buffer
composed of 10 mM HEPES, 5 mM N-methyl-D-glutamine, 5.6 mM KCl, 10 mM D-glucose, and 0.5 mM
CaCl2 (pH 7.4), supplemented with either 280 mM sucrose or 140 mM NaCl and an 80 µL aliquot, was
added to each well of 96-well culture plates. The test compounds and 2(3’)-O-(4-benzoylbenzoyl)-ATP
(BzATP) were then added, and the cells were incubated for 2 h in a humidified 5% CO2 atmosphere at
37 ◦C. After incubation, a Bio-Tek FL600 fluorescence plate reader (Winooski, VT, USA) was used to
measure the absorbance at an excitation wavelength of 530 nm and an emission wavelength of 590 nm.
The inhibition (percent) of ethidium ion uptake was expressed as a relative value of the maximum
accumulation when stimulated with BzATP only. To calculate IC50 values, we calculated a series of
dose–response data using nonlinear regression analysis (i.e., percentage accumulation of ethidium
bromide vs compound concentration). The concentration of ethidium bromide was 0.1 mM.
4.3. NMDA Receptor Antagonist Activity
The functional assay of antagonist activity at the NMDA receptors was performed using primary
cultures of rat cerebellar granule neurons that were prepared according to established protocols [48].
Cells were grown on 10 mm poly-L-lysine coated glass cover slips, and used for the experiments after
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6–9 days in vitro. Cells were loaded with 6 µM Fura-2 AM (ThermoFisher Scientific-Molecular Probes)
for 30 min. Afterwards, the coverslip was mounted on a quartz cuvette containing a Locke-Hepes
buffer using a special holder. Measurements were performed using a PerkinElmer LS-55 fluorescence
spectrometer (Waltham, MA, USA) equipped with a fast-filter accessory, under mild agitation and at
37 ◦C. Analysis of each sample was recorded in real time for 1600 s. After stimulation with NMDA
(100 µM, in the presence of 10 µM glycine), increasing cumulative concentrations of the compound to
be tested were added. The percentages of inhibition at every tested concentration were analyzed using
a non-linear regression curve fitting analysis by using the software GraphPad Prism 5.0 (GraphPad
Software Inc., La Jolla, CA, USA).
Supplementary Materials: Supplementary materials can be accessed online.
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